91
Participants
Start Date
February 6, 2018
Primary Completion Date
December 21, 2020
Study Completion Date
December 21, 2020
TJ301 300mg
TJ301 300mg IV infusion
TJ301 600mg
TJ301 600mg IV infusion
Placebo
Placebo IV infusion
Peking University First Hospital, Beijing
The First Affiliated Hospital, Sun Yat-sen University, Guanzhou
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou
West China Hospital of Sichuan University, Sichuan
Beijing Friendship Hospital Affiliated to the Capital University of Medical Sciences, Beijing
The Seventh Medical Center of PLA Army General Hospital, Beijing
Guangdong Provincial People's Hospital, Guangzhou
Nanfang Hospital of SMU, Guangzhou
Hainan General Hospital, Hainan
Sir Run Run Shaw Hospital Zhejiang University, School of Medicine, Zhejiang
The First Affiliated Hospital of Harbin Medical University, Harbin
The first Bethune hospital of Jilin university, Jilin
The first affiliated hospital of Nanchang Univesity, Nanchang
Jiangsu Province Hospital, Nanjing
The Affiliated Hospital of Nanjing University Medical School, Nanjing
Zhongda Hospital Southeast University, Nanjing
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Xin Hua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
Shengjing hospital of China medical university, Shenyang
Second Hospital of Shanxi Medical University, Shanxi
Tianjin Medical University General Hospital, Tianjin
Yeungnam University Medical Center, Daegu
CHA Bundang Medical Center, CHA University, Seoul
National Taiwan University Hospital, Kaohsiung City
Chang Gung Memorial Hospital, Taipei
Chang Gung Memorial Hospital, Taoyuan District
I-Mab Biopharma HongKong Limited
INDUSTRY